Chiesi's Commercial Hopes In US Hit By FDA Letter
Protalix-Partnered Fabry Drug Turned Down By Agency
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
You may also be interested in...
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.
The prospects of lucerastat becoming Idorsia's second drug to be filed with regulators, after the insomnia treatment daridorexant, look slim after a Phase III fail for the Fabry disease therapy.